FENTANYL DETECTION, EARLY INTERVENTION - 12 PANEL DRUG TEST KIT

The Hawaii Paroling Authority (HPA) is seeking bids for the purchase and delivery of integrated urine-based 12-panel drug testing kits with fentanyl detection capabilities. The kits will support HPA's clinical monitoring, compliance supervision, early intervention, and relapse detection efforts for supervised individuals Statewide. The contract term is from July 1, 2026, to June 30, 2027, with the option to extend for up to three additional 12-month periods. • The testing kits must be capable of detecting the following substances: THC, Buprenorphine, Benzodiazepines, Methadone, Amphetamines, Oxycodone, Opiates, MDMA/Ecstasy, Cocaine, Methamphetamine, Alcohol (EtG), and Fentanyl. • The kits must meet Clinical Laboratory Improvement Amendments (CLIA) standards and be FDA 510(k)-cleared, where applicable. • Vendors must provide product specifications, certifications, and supporting documentation upon request. • The estimated annual quantity is approximately 6,000 testing kits. • The contract will be awarded to the responsive and responsible bidder whose proposal is determined to be most advantageous to the State.